Standardized outcome measures provide a basis for comparing outcomes of different clinical trials. Consequently, they can serve as the foundation for determining which therapeutic interventions are most effective. The aim of the present study is to systematically assess how definitions and outcome measures are defined in therapeutic randomized controlled trials (RCTs) of children with functional constipation (FC).
Results
A total of 4092 articles were found but only 45 studies fulfilled our inclusion criteria. In these 45 trials, 22 different definitions of FC were used (17 studies used the Rome III-criteria), 27 different interventions were investigated, and 29 different definitions of treatment success were used. Thirty RCTs (57%) reported primary outcomes of which treatment success was the most frequently used. Most trials (80%) used parental diaries of which only 2 RCTs stated that their instrument was validated. Twenty four trials (53%) were of good methodological quality.
Conclusions
Inconsistency and heterogeneity exist in definitions and outcome measures used in RCTs on childhood FC. Standard definitions, outcome measures, and also validated instruments are needed. We recommend the development of a minimum core outcome set for clinical research in children with FC to make comparison possible between the effects of different therapeutic interventions across studies.
INTRODUCTION
Constipation is a common pediatric problem worldwide, with a prevalence ranging from 0.7% to 29.6% 1 . In the majority of children, no underlying cause is found and consequently functional constipation (FC) can be diagnosed. Although standard definitions and criteria for FC have been formulated, these are rarely used in research and clinical practice 2 . In 1999, the first diagnostic criteria for various functional gastrointestinal disorders in children were published: the Rome II criteria. Several studies showed that the Rome-II criteria were too restrictive, and therefore in 2006 the modified Rome III criteria were developed [3] [4] [5] . Differences in outcome measurement across clinical trials and inconsistencies in how outcomes are defined and measured make it difficult to pool findings of studies. Furthermore, not all trials provide data on important outcomes, which can cause bias 6 . These inconsistencies and bias could be addressed by the development of agreed standardized sets of outcomes, known as core outcome sets (COS), which should be measured and reported as a minimum in all trials for a specific clinical area 7, 8 . More important, COS are not designed to restrict the outcomes used. Rather, they provide a core set of outcome measures, which researcher should use routinely. Researchers wishing to add other outcome measures pertinent to their trials can do so, but when reporting their results, selective reporting should be avoided through presentation of the findings for both the core set and all additional outcome measures collected. Therefore, COS promote consistency in the availability of information of the effects of interventions on important outcomes 9 . Although COS exist in some clinical area, the use of these sets is still relatively new. The Core Outcome Measures in Effectiveness Trials (COMET) Initiative was launched in 2010 to address the lack of standardized core outcomes measured in clinical trials 10 . The importance of COS is increasingly recognized by research funders, like the National Institute for Health Research in the UK 11 . A minimum COS for research in children with FC would address the problems depicted above. Our group recently showed that different outcome measures and definitions are used in randomized controlled trials (RCTs) regarding FC in infants 2 . The aim of the present study is to assess how definitions and outcomes measures are defined in therapeutic RCTs in children of 1 to 18 years with FC. The results of this review serve the purpose of providing the basis for developing a minimum core set for research in children with FC.
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Data Collection and Analysis
We extracted data on the definition used to describe constipation and its resolution, primary outcomes regarding constipation, and interventions. In order to give an overall impression of the quality of the included trials, we assessed the methodological quality of the included RCT using the Delphi List (http://links. lww.com/MPG/A606) 12 . This scale ranges from 0 (minimum) to 10 (maximum). High quality is defined as a score 60% or more (ie, ≥6 points), low quality as a score <60%. We also extracted key characteristics of study populations, interventions, design, and conduct of each included study. Descriptive statistics are used to illustrate the characteristics of included trials.
RESULTS
Our search strategy provided a total of 4092 articles. After deducting duplicates, 3982 titles and abstracts were evaluated for eligibility. In total, 3834 studies turned out to be irrelevant to our research questions. After full-text screening, another 103 articles were excluded because they did not meet our inclusion criteria (irrelevant to our research question [n=9], study design [n=24], age [n=28], not in English language [n=2]. Eleven articles were excluded because a clear definition of constipation was not provided. An additional 29 articles were systematic reviews describing only RCTs that were already included by our search. Finally, 45 articles were included. A total of 4210 children were included, 2124 were girls and 2086 were boys. In 7 trials (569 patients), the distribution of sexes was not mentioned. The sample sizes varied from 31 to 247 children. Three trials only included children 4 years or younger.
The characteristics of the included studies can be viewed at http://links.lww. com/MPG/A607. Nineteen studies were conducted in Europe, 18 in Asia, 4 in South America, 3 in North America, and 1 in Australia. The majority of the studies recruited patients from tertiary care centers (n=26). Seven trials were conducted in secondary care centers, 6 trials included patients from both secondary and tertiary care centers, and the remaining trials did not report their clinical setting. Only 21 (47%) trials noted a statement on sample size calculation. All trials mentioned their withdrawals and their follow-up period. Adverse effects were reported in 39 (87%) studies.
Definitions of Constipation
In 45 articles, 22 different definitions were used to describe FC (Table 1) . Seventeen articles used the Rome III criteria, 13 other articles used a variation of the Rome III criteria. Two trials used the Rome II criteria and 1 trial used a variation on the Rome II criteria. The remaining 12 articles defined constipation according to their own criteria such as ''pain, difficulty, or delay in defecation during 3 months'' and ''pebble like and hard stool ≥2 times/week for 2 months.''
Therapeutic Interventions for Constipation
As summarized in Table 2 , many different interventions were reported for the treatment of childhood constipation. Treatments could be divided into 2 main categories: pharmacological (47%) and nonpharmacological interventions (53%) including dietary, fiber, pre-and probiotics, and complementary interventions.
Primary Outcome Measures
Thirty studies reported primary and/or secondary outcomes measures. In these 30 trials, at least 1 primary outcome was mentioned ( Table 3) . Treatment success was often chosen as primary outcome measure (n=17), followed by defecation frequency (n=12) and fecal incontinence frequency (n¼8). Treatment success was reported in 31 articles (69%), but definitions of treatment success varied widely, resulting in 29 different definitions ( Table 4 ).
Validity of Used Instrument
Twenty-four of the 30 studies (80%) reporting their primary outcomes measures, used patient/parental diaries or questionnaires to measure these outcomes. Only 2 articles stated that their instruments were validated (Clarke 2005 and Keshtgar 2007 ). Three trials evaluated their primary outcome measure during clinic visits, 1 trial by measuring colonic transit time and 1 trial (Wang 2012) did not mention how their primary outcome was assessed. Only 8 of 20 trials describing stool consistency used the internationally available Bristol Stool Scale to assess this outcome measure 13 .
Methodological Quality
The Delphi List was used to assess the methodological quality of the included RCTs 12 . Outcomes were used for a general impression of the methodological quality of the included articles. Fifty-three percent of the trials had a Delphi Score of 6 or more, indicating a good methodological quality. There was, however, an important difference between the methodological quality of the pharmacologic and the nonpharmacologic trials. The majority of the nonpharmacological trials (72%) is of high quality, whether most pharmacological trials are of low quality (70%). This difference is caused by the lack of information regarding blinding and the allocation concealment in most pharmacological trials.
DISCUSSION
To our knowledge, this is the first study assessing definitions and outcome measures related to FC in children from 1 to 18 years old. Although the majority of the trials were of high methodological quality, our data demonstrate inconsistency in choice and definition of outcomes in trials regarding childhood FC that is comparable with our earlier study. In 45 trials, 22 different definitions of FC and 29 different definitions of treatment success were reported. Only 17 trials used the internationally accepted Rome III criteria. It is unclear why trials conducted after the publication of the Rome III criteria did not use these criteria. Another explanation is that a study from the United States revealed that 99% of pediatric gastroenterologists knew about the Rome III criteria, but only 71% used them in daily practice 14, 15 . Moreover, only 45% found them useful for clinical practice, indicating that the present Rome definition for constipation is not implemented in clinical practice and research. This may be due to the fact that the present Rome III is still too restrictive for clinical practice. Another reason can be related to barriers of individual physicians. They may not follow recommendations because of difficulties of changing habits or old routines or having a lack of motivation 16 . Table 3b Definitions of treatment success ecause comparing treatment success is the base for determining which intervention comprise best clinical practice, it is surprising that a definition of treatment success was only reported in 69% of the articles. One of the most remarkable findings of our study is that 15 of 45 (33%) trials did not report whether their outcome measures were primary or secondary endpoints. This is important, because this is essential in the design of RCTs to set out in advance the endpoints that need to be assessed. Moreover, sample size calculation, based on chosen endpoints, are necessary to determine the number of participants needed to detect a clinically relevant treatment effect. Because failure to prespecify endpoints can introduce bias and create opportunities for manipulation 17 . Although treatment success was most often used as primary endpoint, the definitions of treatment success varied widely. It is essential to select the right outcome to measure treatment success, because use of incorrect outcomes is a waste of resources, both for the researchers and participants involved in the trials and importantly, it does not answer the research question. Presentation of results from inappropriate outcomes is therefore misleading and results in bias 18 .
Differences in definitions and treatment outcomes could be due to the fact that some studies may be initiated by health care practitioners whereas other studies are industry-driven, and consequently have different interests. It is therefore important to involve all stakeholders in the development of COS in an early stage. Interestingly, patient or parent satisfaction and quality of life were only evaluated in a small minority of the trials. Because today's health care is focused on patient-and family-centered care, integrating patients' perspectives into clinical practice and research using questionnaires that measure patients' experiences of their health (patient reported outcome measures) are of growing importance 19 . In addition, most studies did not use validated instruments to report on outcome measures. The Bristol Stool Scale or Amsterdam Infant Stool Scale could be useful instruments to report stool consistency 20 . The lack of using validated instruments assessing childhood FC and the variety of the present outcome measures make it difficult to perform meta-analyses. Adverse effects were reported in the majority (87%) of trials. The possibility of occurrence of adverse effects is an important element when exploring effectiveness of interventions for childhood FC and should therefore always be evaluated in future RCTs. Inconsistency and heterogeneity in outcome reporting across studies will finally influence therapeutic recommendations in guidelines and thus clinical practice 6 . In order to avoid inconsistency and heterogeneity across studies, a standardized outcome set is needed. Our results highlight the need, and comprise the first step, to develop a minimum core outcome set for childhood constipation. Presently, there is no COS for childhood constipation. With regard to outcomes, the Food and Drug Administration guidelines encourage involving patients in the development of patient reported outcome measures 21 .
Patients and parents should directly be asked what they consider to be the most relevant outcomes concerning FC. The list of outcomes identified by this systematic review will, together with outcomes identified by pediatricians, pediatric gastroenterologists, and parents of children with FC, provide the basis of the future COS.
There are some limitations. First, it is possible that we did not include all relevant RCTs. We did not, however, aim to include all RCTs available because it was not our objective to perform a meta-analysis evaluating the efficacy of the different therapeutic interventions. Rather, we aimed to acquire a comprehensive sample of trials for the evaluation of used definitions and outcome measures for childhood constipation. By including only English written studies we may have caused bias by missing studies that used different definitions and outcomes. One could, however, assume that relevant studies are published in English to create worldwide accessibility. The second limitation of our study is the evaluation of the methodological quality of included articles using the Delphi List. This scale does not include all of the items that are associated with the risk of bias. Furthermore, it assigns ''weight'' to different items in the scale by providing an overall score per trial. The Risk of Bias tool would have been as good alternative, because it contains addition items associated with bias, if it was our goal to use scores for eligibility criteria or to conduct subgroup analyses 22 . It was, however, only our aim to give an overall impression of our sample size.
CONCLUSION
In the present review, we highlighted inconsistency and heterogeneity in reporting definitions and outcome measures used in trials concerning childhood FC. In order to compare different studies, we recommend the further development of a COS for clinical research in children with FC. As next step, we will involve health care professionals and caregivers in the development of COS.
